• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Outcomes of heart transplant recipients with prior left ventricular assist device associated stroke
Left ventricular assist devices (LVADs) improve survival in patients with end-stage heart failure but are associated with ischemic stroke and intracranial hemorrhage (ICH). The impact of LVAD-associated stroke on transplant candidacy and outcomes has not been characterized.
Source: Journal of Stroke and Cerebrovascular Diseases - June 7, 2023 Category: Neurology Authors: Aaron Shoskes, Merry Huang, Catherine Hassett, Randall C Starling, Eileen Hsich, Edward Soltesz, Sung-Min Cho, Ken Uchino Source Type: research

Management of Intracranial Hemorrhage in Patients with a Left Ventricular Assist Device: A Systematic Review and Meta-Analysis
Left Ventricular Assist Device (LVAD) therapy serves as a surgically implanted form of mechanical circulation in patients with advanced heart failure. Initially designed to provide a bridge to transplant, LVADs now offer an alternative that is increasingly utilized as final destination therapy as the need for donor hearts increases worldwide.1,2 However, this requires lifelong anticoagulation (AC) to prevent pump thrombosis, resulting in hemorrhagic risks.3
Source: Journal of Stroke and Cerebrovascular Diseases - December 1, 2020 Category: Neurology Authors: Austin H. Carroll, Michael P. Ramirez, Ehsan Dowlati, Kyle B. Mueller, Ali Borazjani, Jason J. Chang, Daniel R. Felbaum Tags: Review Article Source Type: research

Radiographic risk factors for intracranial hemorrhage in patients with left ventricular assist devices
Patients with end-stage cardiomyopathy may require the use of mechanical circulatory support to maintain perfusion of the vital organs. This is most commonly achieved using an implantable left ventricular assist device (LVAD), typically used as a bridge to orthotopic heart transplant (BTT) or as destination therapy (DT) for those who are not transplant candidates. An LVAD is usually considered for those patients whose disease and symptoms meet INTERMACS Levels 2-4 criteria, indicating a significant decrease in functionality.
Source: Journal of Stroke and Cerebrovascular Diseases - November 1, 2022 Category: Neurology Authors: Nicholas S. Hernandez, Matthew Kanter, Vaishnavi Sharma, Andy Wang, Michael Kiernan, Delia Kryzanski, Robert Heller, Tara Nail, Ron I. Riesenburger, James T. Kryzanski Source Type: research